A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

Am J Hematol. 2019 Nov;94(11):E291-E294. doi: 10.1002/ajh.25605. Epub 2019 Aug 20.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / administration & dosage
  • Bortezomib / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / analogs & derivatives
  • Febrile Neutropenia / chemically induced
  • Female
  • Humans
  • Hydroxyurea / administration & dosage
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Neoplastic Cells, Circulating
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / adverse effects
  • Progression-Free Survival
  • Proteasome Inhibitors / administration & dosage
  • Proteasome Inhibitors / adverse effects
  • Treatment Outcome

Substances

  • Proteasome Inhibitors
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Bortezomib
  • Doxorubicin
  • Hydroxyurea